Milestone Pharmaceuticals upgraded to Buy at TD Cowen after Cardamyst approval [Yahoo! Finance]
Milestone Pharmaceuticals Inc. - Common Shares (MIST)
Last milestone pharmaceuticals inc. - common shares earnings: 3/6 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
was approved by the FDA for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm in adults. The label is clean with no market-limiting warnings or monitoring requirements, notes the analyst, who also points out that Cardamyst will be available in retail pharmacies in Q1 of 2026 with a wholesale acquisition cost of $1,649. Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now See today's best-performing stocks on TipRanks Read More on MIST: Disclaimer & Disclosure Report an Issue Milestone Pharmaceuticals upgraded to Buy from Hold at TD Cowen Milestone Pharmaceuticals Poised for Success with Cardamyst Approval and Strong Market Potential
Show less
Read more
Impact Snapshot
Event Time:
MIST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIST alerts
High impacting Milestone Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
MIST
News
- Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.MarketBeat
- Milestone Pharmaceuticals announces U.S. availability of cardamyst [Yahoo! Finance]Yahoo! Finance
- Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) [Yahoo! Finance]Yahoo! Finance
- Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)GlobeNewswire
MIST
Earnings
- 11/12/25 - Beat
MIST
Sec Filings
- 2/5/26 - Form 4/A
- 2/5/26 - Form 4/A
- 2/5/26 - Form 4/A
- MIST's page on the SEC website